Pharmaceuticals, Biotechnology and Life Sciences
Oxular Limited, a retinal therapeutics company, has promoted David Fellows, previously Non-Executive Director, as the Company’s Chairman of the Board. Fellows will replace Dr. Nigel Pitchford, who will continue on Oxular’s Board as a Director.
Bristol-Myers Squibb (BMS) has reached a payment milestone in connection with the licensing deal with Innate Pharma for lirilumab in combination with Opdivo. BMS has paied Innate $15 million.
Sweden-based pharmaceutical company Orphan Biovitrum AB (Sobi) has began looking for the new Chief Executive Officer (CEO), presumably a residence of Europe. The company said on Monday that its current boss, Geoffrey McDonough will leave the company in six months, on July 1, 2017.
On January 4, 2017, TiGenix received a transparency notification from related companies Takeda Pharmaceutical Company Limited/Takeda Pharmaceuticals International AG, following…
Argenx, a European biopharmaceutical company focused on drugs for the treatment of cancer and autoimmune diseases, has initiated a Phase…
U.S. Patent and Trade Office (USPTO) has decided to uphold Celyad’s U.S. Patent No. 9,181,527, relating to allogeneic human primary…
Author: Anna Michael, The Study Abroad Portal The Study Abroad Portal helps students worldwide to make the right decision with…
Ipsen has acquired global oncology assets from Merrimack Pharmaceuticals. This acquisition includes Merrimack’s key marketed product Onivyde (irinotecan liposome injection)…
e-Therapeutics plc, the drug discovery company, has made further steps in transitioning its business as it picked Amgen Inc.’s Corporate Development Executive Director, Dr. Raymond Barlow as its new Chief Executive Officer (CEO) who assume his position before May 1, 2017.
AB Sciences has more reasons to believe that its protein kinase inhibitor (PKI) masitinib could have FDA’s further clearence, as the results from the pivotal phase 3 study have been published in highly regarded independent general medical journal, The Lancet.